The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.

Volume: 21, Issue: 10, Pages: 1071 - 1080
Published: Aug 9, 2021
Abstract
EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are being tested to overcome or...
Paper Details
Title
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.
Published Date
Aug 9, 2021
Volume
21
Issue
10
Pages
1071 - 1080
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.